2
Announcements
Trials
Browse
Landscape
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Observational
1
Sponsor
Cancer Type
Thoracic
1
Plasma cell
1
Other hematologic neoplasm
1
Myeloid
1
Lymphoid
1
Genitourinary
1
Gastrointestinal
1
Classical hematology
1
Breast
1
Conditions
Venous Thromboembolism
8
Venous Thrombosis
6
Neoplasms
6
Pulmonary Embolism
5
Thromboembolism
3
Lung Neoplasms
3
Multiple Myeloma
2
Lymphoma
2
Colorectal Neoplasms
2
Vascular Diseases
1
Urogenital Neoplasms
1
Thrombosis
1
Thrombocytopenia
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Myeloproliferative Disorders
1
Lymphoproliferative Disorders
1
Lymphatic Diseases
1
Liver Neoplasms
1
Leukemia
1
Kidney Neoplasms
1
Intestinal Neoplasms
1
Hemostatic Disorders
1
Hemorrhage
1
Digestive System Neoplasms
1
Colonic Neoplasms
1
Carcinoma, Renal Cell
1
Carcinoma, Ovarian Epithelial
1
Carcinoma, Non-Small-Cell Lung
1
Breast Neoplasms
1
Interventions
Irinotecan
10
Fluorouracil
10
Leucovorin
9
Bevacizumab
9
Gemcitabine
8
Paclitaxel
7
Cisplatin
7
Capecitabine
7
Oxaliplatin
6
130-nm albumin-bound paclitaxel
6
Albumin-Bound Paclitaxel
5
napabucasin
4
Sorafenib
4
Drug Therapy
4
Cetuximab
4
pembrolizumab
3
apatinib
3
Radiotherapy
3
Ocoxin
3
Imatinib Mesylate
3
Folfox protocol
3
Everolimus
3
tislelizumab
2
spartalizumab
2
palbociclib
2
entinostat
2
encorafenib
2
camrelizumab
2
anlotinib
2
Sunitinib
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Digestive System Neoplasms
×
Tinzaparin
×
Clear all
NCT03099031
2019-12-16
PREDICARE
LEO Pharma
Completed
420 enrolled